Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Disease Models Will Focus On Areas With Poor R&D Track Records

Executive Summary

FDA's disease state modeling efforts may focus on therapeutic areas which traditionally have suboptimal drug development, Office of Clinical Pharmacology & Biopharmaceutics Director Larry Lesko said

You may also be interested in...



FDA Probes How To Compile Clinical Trial Data; Legal, Scientific Barriers Remain

Despite having gathered large amounts of clinical trial data through the years, FDA faces challenges when it comes to analyzing the data outside of the original scope in which it was collected

FDA Probes How To Compile Clinical Trial Data; Legal, Scientific Barriers Remain

Despite having gathered large amounts of clinical trial data through the years, FDA faces challenges when it comes to analyzing the data outside of the original scope in which it was collected

Industry Encouraged To Spread Its Wings In Learn Phase of Adaptive Trials

While FDA is granting industry a great deal of leeway in designing early, learn-phase adaptive trial models, the agency is suggesting that emphasis be placed on dose response and exposure risk, FDA officials indicated at a recent Pharmaceutical Research & Manufacturers of America workshop

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS046588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel